Hepatitis B core-related antigen levels predict pegylated interferon-α therapy response in HBeAg-positive chronic hepatitis B [0.03%]
乙肝核心相关抗原水平可预测HBeAg阳性慢性乙型肝炎患者干扰素治疗的反应结果
Boris Jb Beudeker,Zwier Ma Groothuismink,Robert A de Man et al.
Boris Jb Beudeker et al.
Background: Serum hepatitis B core-related antigen (HBcrAg) levels reflect intrahepatic HBV replication activity. We aimed to study whether HBcrAg levels predict response to pegylated interferon (PEG-IFN) treatment in hep...
Randomized Controlled Trial
Antiviral therapy. 2020;25(4):217-222. DOI:10.3851/IMP3367 2020
Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring system [0.03%]
利用分层评分系统评估COVID-19的潜在新用途药物
Michael A Jarvis,Frederick A Hansen,Kyle Rosenke et al.
Michael A Jarvis et al.
Background: As the coronavirus disease 2019 (COVID-19) pandemic grows daily, we remain with no prophylactic and only minimal therapeutic interventions to prevent or ameliorate severe acute respiratory syndrome Coronavirus...
Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects [0.03%]
口服TLR8激动剂塞甘托利莫德的安全性、药代动力学和药效学：健康受试者Ia期临床试验
Maribel Reyes,Justin D Lutz,Audrey H Lau et al.
Maribel Reyes et al.
Background: Selgantolimod is a novel oral, selective Toll-like receptor 8 (TLR8) agonist in development for the treatment of chronic hepatitis B (CHB). TLR8 is an endosomal innate immune receptor and a target for treatmen...
Clinical Trial
Antiviral therapy. 2020;25(3):171-180. DOI:10.3851/IMP3363 2020
Dynamics of HBV surface antigen related end points in chronic hepatitis B infection: a systematic review and meta-analysis [0.03%]
慢性乙型肝炎感染中HBV表面抗原相关指标的动态变化：系统评价和meta分析
Yusi Chen,Justin Jinhui Li,Rong Chen et al.
Yusi Chen et al.
Background: In chronic hepatitis B (CHB) treatment, hepatitis B surface antigen (HBsAg) is regarded as a promising clinical end point associated with long-term clinical outcomes. We performed a meta-analysis to characteri...
Meta-Analysis
Antiviral therapy. 2020;25(4):203-215. DOI:10.3851/IMP3366 2020
The effects of nucleoside/nucleotide analogues on host immune cells: the baseline for future immune therapy for HBV? [0.03%]
核苷(酸)类似物对宿主免疫细胞的影响：未来乙型肝炎免疫治疗的基础？
Lauke L Boeijen,Michelle Spaan,André Boonstra
Lauke L Boeijen
HBV is a non-cytopathic virus and the progression of liver fibrosis is attributed to the host immune response. Complete suppression of viral replication using nucleotide or nucleoside analogues (NUCs) can prevent most complications related ...
SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection [0.03%]
针对SARS-CoV-2和HIV蛋白酶抑制剂：为什么洛匹那韦/利托那韦无法治疗COVID-19感染
Elise J Smolders,Lindsey Hm Te Brake,David M Burger
Elise J Smolders
Since the beginning of the outbreak of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2, lopinavir/ritonavir was selected for treatment. The recent publication of Cao et al. in the New England Journal of Medicine showed that lop...
Antiviral activity of PLK1-targeting siRNA delivered by lipid nanoparticles in HBV-infected hepatocytes [0.03%]
HBV感染的肝细胞中由脂质纳米颗粒递送的PLK1靶向siRNA的抗病毒活性
Adrien Foca,Ammen Dhillon,Thomas Lahlali et al.
Adrien Foca et al.
Background: A link between HBV and PLK1 was clearly evidenced in HBV-driven carcinogenesis, and we have also recently shown that PLK1 is a proviral factor in the early phases of HBV infection. Moreover, we have shown that...
Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19 [0.03%]
含洛匹那韦/利托那韦、阿比多尔和干扰素-α1b的抗新型冠状病毒(SARS-CoV-2)肺炎药物组合疗法
Xiangyang Xie,Yuanliang Jiang,Yuan Zeng et al.
Xiangyang Xie et al.
Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high i...
Case Reports
Antiviral therapy. 2020;25(4):233-239. DOI:10.3851/IMP3362 2020
Factors influencing hair lamivudine concentration among people living with HIV in Guangxi, China [0.03%]
广西地区艾滋病患者头发中拉米夫定浓度的影响因素分析
Quan Zhang,Xiaoming Li,Shan Qiao et al.
Quan Zhang et al.
Background: Hair antiretroviral concentration has served as an innovative and objective measure of antiretroviral adherence. However, some factors (for example, pharmacokinetics and hair characteristics) may contribute to...
Activation of HIV-specific CD8+ T-cells from HIV+ donors by vesatolimod [0.03%]
HIV感染供体的CD8+T细胞通过vesatolimod激活
Renee R Ram,Paul Duatschek,Nicolas Margot et al.
Renee R Ram et al.
Background: Vesatolimod (VES; GS-9620) is a Toll-like receptor 7 (TLR7) agonist that directly activates human plasmacytoid dendritic cells (pDCs) and B lymphocytes resulting in direct and indirect production of cytokines ...